<p>Revvity Inc.（紐約證券交易所代碼：RVTY - 獲取免費報告）在覆蓋該公司的十三位分析師中獲得了 “持有” 的共識推薦，MarketBeat 報道稱。一位投資分析師對該股票給予了賣出推薦，六位分析師給予了持有推薦，六位分析師則給予了買入推薦。在過去一年中，對該股票發佈評級的券商的平均 12 個月目標價為 113.9091 美元。</p>
<p>多家股票分析師對 RVTY 股票發佈了報告。巴克萊在 12 月 15 日的研究報告中將 Revvity 的目標價從 105.00 美元上調至 115.00 美元，並給予該股票 “增持” 評級。Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 Revvity 的 “賣出（d）” 評級。高盛集團在 12 月 9 日的報告中開始覆蓋 Revvity 股票。他們給予了 “中性” 評級，並設定了 105.00 美元的目標價。美國銀行在 12 月 15 日的研究報告中將 Revvity 的評級從 “買入” 下調至 “中性”，並設定了 110.00 美元的目標價。最後，Evercore ISI 在 1 月 5 日的研究報告中重新發布了對 Revvity 的 “跑贏大盤” 評級。</p>
<p><strong>閲讀我們關於 Revvity 的最新研究報告</strong></p>
<h2>機構投資者對 Revvity 的看法</h2>
<p>多家對沖基金最近增持或減持了 RVTY 的股份。CYBER HORNET ETFs LLC 在第二季度新購入了 Revvity 的股份，價值約 32,000 美元。Cromwell Holdings LLC 在第四季度將其在 Revvity 的持股增加了 141.4%。Cromwell Holdings LLC 現在擁有 338 股該公司的股票，價值 33,000 美元，此前在上個季度又購買了 198 股。MUFG Securities EMEA plc 在第二季度新購入了 Revvity 的股份，價值 34,000 美元。UMB Bank n.a. 在第二季度將其在 Revvity 的持股增加了 138.8%。UMB Bank n.a. 現在擁有 406 股該公司的股票，價值 39,000 美元，此前在上個季度又購買了 236 股。最後，CVA Family Office LLC 在第二季度將其在 Revvity 的持股增加了 79.0%。CVA Family Office LLC 現在擁有 410 股該公司的股票，價值 40,000 美元，此前在上個季度又購買了 181 股。機構投資者和對沖基金持有該公司 86.65% 的股份。</p>
<h2>Revvity 股票表現</h2>
<p>RVTY 股票在週五開盤價為 116.64 美元。該公司的市值為 132.2 億美元，市盈率為 58.61，市盈增長比率為 3.57，貝塔值為 1.05。該公司的流動比率為 1.75，速動比率為 1.44，債務與股本比率為 0.36。該股票的 50 日移動平均價格為 102.18 美元，200 日移動平均價格為 95.02 美元。Revvity 的一年低點為 81.36 美元，一年高點為 128.29 美元。</p>
<p>Revvity（紐約證券交易所代碼：RVTY - 獲取免費報告）在 10 月 27 日發佈了最新的財報。該公司報告本季度每股收益為 1.18 美元，超出市場共識預期的 1.14 美元，超出 0.04 美元。該季度的營業收入為 6.9895 億美元，而分析師預期為 6.9975 億美元。Revvity 的股本回報率為 7.52%，淨利潤率為 8.44%。該公司的收入同比增長 2.2%。去年同期，該公司每股收益為 1.28 美元。Revvity 將其 2025 財年的指導目標設定為 4.900-5.000 美元每股。整體來看，股票研究分析師預計 Revvity 今年將發佈 4.94 美元的每股收益。</p>
<p>Revvity 宣佈其董事會在 10 月 27 日授權了一項股票回購計劃，允許公司回購 10 億美元的流通股。該回購授權允許公司通過公開市場購買回購最多 8.7% 的股份。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
<h2>關於 Revvity</h2>
<p>（獲取免費報告）</p>
<p>Revvity, Inc 是一家全球領先的生命科學、診斷和應用市場的技術解決方案提供商。該公司開發和提供一系列產品和服務，包括試劑和耗材、實驗室儀器、工作流程自動化、軟件分析和技術支持。其產品組合支持藥物發現、基因組學、細胞生物學研究、環境和食品安全檢測、工業質量控制和臨牀診斷等應用。</p>
<p>Revvity 的歷史可以追溯到 1937 年成立的 Perkin-Elmer，Revvity 於 2024 年 1 月在紐約證券交易所以 RVTY 的股票代碼開始交易，經過企業品牌重塑。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票比 Revvity 更好</li>
<li>家族信託如何幫助保護您的財富</li>
<li>請勿刪除，立即閲讀</li>
<li>沒有人告訴你的 100 萬億美元的人工智能故事</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 您的銀行賬户</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJWVFk?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJWVFk"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Revvity 嗎？</h2>
<p>在您考慮 Revvity 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Revvity 並不在名單上。</p>
<p>雖然 Revvity 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RVTY

<p>Revvity Inc.（紐約證券交易所代碼：RVTY）獲得了十三位分析師的 “持有” 共識評級。該股票有一項賣出、六項持有和六項買入建議。12 個月的平均目標價為 113.91 美元。巴克萊將其目標價上調至 115 美元，而美國銀行則下調至 110 美元。Revvity 的股票開盤價為 116.64 美元，市值為 132.2 億美元。該公司報告了上個季度每股收益為 1.18 美元，超出預期，並宣佈了一項 10 億美元的股票回購計劃，顯示出對其股票價值的信心</p>

<p>Revvity Inc. (NYSE:RVTY - Get Free Report) has earned a consensus recommendation of &#34;Hold&#34; from the thirteen analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $113.9091.</p>
<div class="lb-trans"><p>Revvity Inc.（紐約證券交易所代碼：RVTY - 獲取免費報告）在覆蓋該公司的十三位分析師中獲得了 “持有” 的共識推薦，MarketBeat 報道稱。一位投資分析師對該股票給予了賣出推薦，六位分析師給予了持有推薦，六位分析師則給予了買入推薦。在過去一年中，對該股票發佈評級的券商的平均 12 個月目標價為 113.9091 美元。</p>
</div><p>A number of equities analysts have issued reports on RVTY shares. Barclays raised their price objective on shares of Revvity from $105.00 to $115.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, December 15th. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Revvity in a research note on Monday, December 29th. The Goldman Sachs Group initiated coverage on shares of Revvity in a report on Tuesday, December 9th. They issued a &#34;neutral&#34; rating and a $105.00 price target for the company. Bank of America downgraded shares of Revvity from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $110.00 price target for the company. in a research note on Monday, December 15th. Finally, Evercore ISI reissued an &#34;outperform&#34; rating on shares of Revvity in a research report on Monday, January 5th.</p>
<div class="lb-trans"><p>多家股票分析師對 RVTY 股票發佈了報告。巴克萊在 12 月 15 日的研究報告中將 Revvity 的目標價從 105.00 美元上調至 115.00 美元，並給予該股票 “增持” 評級。Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 Revvity 的 “賣出（d）” 評級。高盛集團在 12 月 9 日的報告中開始覆蓋 Revvity 股票。他們給予了 “中性” 評級，並設定了 105.00 美元的目標價。美國銀行在 12 月 15 日的研究報告中將 Revvity 的評級從 “買入” 下調至 “中性”，並設定了 110.00 美元的目標價。最後，Evercore ISI 在 1 月 5 日的研究報告中重新發布了對 Revvity 的 “跑贏大盤” 評級。</p>
</div><p><strong>Read Our Latest Research Report on Revvity</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Revvity 的最新研究報告</strong></p>
</div><h2>Institutional Investors Weigh In On Revvity</h2>
<div class="lb-trans"><h2>機構投資者對 Revvity 的看法</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in RVTY. CYBER HORNET ETFs LLC acquired a new position in shares of Revvity during the second quarter worth approximately $32,000. Cromwell Holdings LLC raised its holdings in Revvity by 141.4% during the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company's stock worth $33,000 after buying an additional 198 shares during the last quarter. MUFG Securities EMEA plc acquired a new position in Revvity during the second quarter worth $34,000. UMB Bank n.a. lifted its stake in shares of Revvity by 138.8% in the second quarter. UMB Bank n.a. now owns 406 shares of the company's stock valued at $39,000 after buying an additional 236 shares in the last quarter. Finally, CVA Family Office LLC grew its holdings in shares of Revvity by 79.0% during the second quarter. CVA Family Office LLC now owns 410 shares of the company's stock valued at $40,000 after buying an additional 181 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company's stock.</p>
<div class="lb-trans"><p>多家對沖基金最近增持或減持了 RVTY 的股份。CYBER HORNET ETFs LLC 在第二季度新購入了 Revvity 的股份，價值約 32,000 美元。Cromwell Holdings LLC 在第四季度將其在 Revvity 的持股增加了 141.4%。Cromwell Holdings LLC 現在擁有 338 股該公司的股票，價值 33,000 美元，此前在上個季度又購買了 198 股。MUFG Securities EMEA plc 在第二季度新購入了 Revvity 的股份，價值 34,000 美元。UMB Bank n.a. 在第二季度將其在 Revvity 的持股增加了 138.8%。UMB Bank n.a. 現在擁有 406 股該公司的股票，價值 39,000 美元，此前在上個季度又購買了 236 股。最後，CVA Family Office LLC 在第二季度將其在 Revvity 的持股增加了 79.0%。CVA Family Office LLC 現在擁有 410 股該公司的股票，價值 40,000 美元，此前在上個季度又購買了 181 股。機構投資者和對沖基金持有該公司 86.65% 的股份。</p>
</div><h2>Revvity Stock Performance</h2>
<div class="lb-trans"><h2>Revvity 股票表現</h2>
</div><p>RVTY stock opened at $116.64 on Friday. The firm has a market cap of $13.22 billion, a PE ratio of 58.61, a price-to-earnings-growth ratio of 3.57 and a beta of 1.05. The company has a current ratio of 1.75, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The stock has a 50-day moving average price of $102.18 and a 200-day moving average price of $95.02. Revvity has a 1-year low of $81.36 and a 1-year high of $128.29.</p>
<div class="lb-trans"><p>RVTY 股票在週五開盤價為 116.64 美元。該公司的市值為 132.2 億美元，市盈率為 58.61，市盈增長比率為 3.57，貝塔值為 1.05。該公司的流動比率為 1.75，速動比率為 1.44，債務與股本比率為 0.36。該股票的 50 日移動平均價格為 102.18 美元，200 日移動平均價格為 95.02 美元。Revvity 的一年低點為 81.36 美元，一年高點為 128.29 美元。</p>
</div><p>Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Monday, October 27th. The company reported $1.18 EPS for the quarter, topping the consensus estimate of $1.14 by $0.04. The business had revenue of $698.95 million during the quarter, compared to analysts' expectations of $699.75 million. Revvity had a return on equity of 7.52% and a net margin of 8.44%.The firm's revenue was up 2.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.28 earnings per share. Revvity has set its FY 2025 guidance at 4.900-5.000 EPS. As a group, equities research analysts expect that Revvity will post 4.94 earnings per share for the current year.</p>
<div class="lb-trans"><p>Revvity（紐約證券交易所代碼：RVTY - 獲取免費報告）在 10 月 27 日發佈了最新的財報。該公司報告本季度每股收益為 1.18 美元，超出市場共識預期的 1.14 美元，超出 0.04 美元。該季度的營業收入為 6.9895 億美元，而分析師預期為 6.9975 億美元。Revvity 的股本回報率為 7.52%，淨利潤率為 8.44%。該公司的收入同比增長 2.2%。去年同期，該公司每股收益為 1.28 美元。Revvity 將其 2025 財年的指導目標設定為 4.900-5.000 美元每股。整體來看，股票研究分析師預計 Revvity 今年將發佈 4.94 美元的每股收益。</p>
</div><p>Revvity declared that its board has authorized a share repurchase program on Monday, October 27th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 8.7% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's board believes its shares are undervalued.</p>
<div class="lb-trans"><p>Revvity 宣佈其董事會在 10 月 27 日授權了一項股票回購計劃，允許公司回購 10 億美元的流通股。該回購授權允許公司通過公開市場購買回購最多 8.7% 的股份。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
</div><h2>About Revvity</h2>
<div class="lb-trans"><h2>關於 Revvity</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.</p>
<div class="lb-trans"><p>Revvity, Inc 是一家全球領先的生命科學、診斷和應用市場的技術解決方案提供商。該公司開發和提供一系列產品和服務，包括試劑和耗材、實驗室儀器、工作流程自動化、軟件分析和技術支持。其產品組合支持藥物發現、基因組學、細胞生物學研究、環境和食品安全檢測、工業質量控制和臨牀診斷等應用。</p>
</div><p>Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.</p>
<div class="lb-trans"><p>Revvity 的歷史可以追溯到 1937 年成立的 Perkin-Elmer，Revvity 於 2024 年 1 月在紐約證券交易所以 RVTY 的股票代碼開始交易，經過企業品牌重塑。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Revvity</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Do not delete, read immediately</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Revvity 更好</li>
<li>家族信託如何幫助保護您的財富</li>
<li>請勿刪除，立即閲讀</li>
<li>沒有人告訴你的 100 萬億美元的人工智能故事</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 您的銀行賬户</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJWVFk" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=RVTY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Revvity Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Revvity 嗎？</h2>
</div><p>Before you consider Revvity, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Revvity 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Revvity 並不在名單上。</p>
</div><p>While Revvity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Revvity 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Revvity Inc.（NYSE 代碼：RVTY）被分析師一致評級為 “持有”